New sleeping pill not likely to be overused
Key points
- A new medication recently approved for insomnia treatment does not appear to have any characteristics that might lead to dependence or abuse, researchers report.
- The sleep aid, Rozerem (known generically as ramelteon), acts in the same way as melatonin, the natural hormone that has been linked to healthy sleep in numerous studies.
- Because of concerns about mental confusion and becoming dependent, "physicians and patients alike are often wary of using sleeping medications," Dr.
- Griffiths and colleagues at the Johns Hopkins University School of Medicine, Baltimore, Maryland conducted a study involving 14 patients with a history of sedative abuse, over a period of about 18 days in a residential research facility.
A new medication recently approved for insomnia treatment does not appear to have any characteristics that might lead to dependence or abuse, researchers report.
The sleep aid, Rozerem (known generically as ramelteon), acts in the same way as melatonin, the natural hormone that has been linked to healthy sleep in numerous studies.
Because of concerns about mental confusion and becoming dependent, "physicians and patients alike are often wary of using sleeping medications," Dr. Roland R. Griffiths told Reuters Health. "Our study found no evidence of potential for abuse or impairing effects of ramelteon up to 20 times the recommended therapeutic dose."
Griffiths and colleagues at the Johns Hopkins University School of Medicine, Baltimore, Maryland conducted a study involving 14 patients with a history of sedative abuse, over a period of about 18 days in a residential research facility.
On different days and in random order, the participants received three different doses of ramelteon, three different doses of the sedative triazolam, or an inactive placebo pill.
Ramelteon had no significant effects on cognition or movement control and no apparent potential for abuse, the team reports in the Archives of General Psychiatry. In fact, 11 of the subjects thought that ramelteon at its highest dose was actually a placebo.
Conversely, subjects and observers agreed that triazolam had a wide range of dose-related effects on motor and cognitive performance.
"Ramelteon represents a useful alternative to existing insomnia medications that could have broad appeal to patients who are otherwise reluctant to use such compounds," Griffiths concluded.
SOURCE: Archives of General Psychiatry, October 2006.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Sleep →
NewsWhen it comes to sleep research, fruit flies and people make unlikely bedfellows
You may never hear fruit flies snore, but rest assured that when you're asleep they are too. According to research published in the January 2009 issue of the journal GENETICS, scientists from the University of…
13 January 2009
NewsCollege students involved in extracurricular activities are more likely to have sleep deprivation
College students involved in extracurricular activities are more likely to have sleep deprivation and be sleepy during the daytime, which can negatively affect their academic performance, according to a research…
9 June 2008
NewsWomen worrying about cancer are more likely to experience sleep disturbances
A significant number of women worrying about cancer may be experiencing sleep disturbances, even without a breast cancer diagnosis, according to a research abstract that will be presented by Amita Dharawat, MD, on…
